Search

Your search keyword '"Barentsz, Jelle O."' showing total 799 results
Start Over Author "Barentsz, Jelle O."
799 results on '"Barentsz, Jelle O."'

4. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel

Author

Westphalen, Antonio C, McCulloch, Charles E, Anaokar, Jordan M, Arora, Sandeep, Barashi, Nimrod S, Barentsz, Jelle O, Bathala, Tharakeswara K, Bittencourt, Leonardo K, Booker, Michael T, Braxton, Vaughn G, Carroll, Peter R, Casalino, David D, Chang, Silvia D, Coakley, Fergus V, Dhatt, Ravjot, Eberhardt, Steven C, Foster, Bryan R, Froemming, Adam T, Fütterer, Jurgen J, Ganeshan, Dhakshina M, Gertner, Mark R, Mankowski Gettle, Lori, Ghai, Sangeet, Gupta, Rajan T, Hahn, Michael E, Houshyar, Roozbeh, Kim, Candice, Kim, Chan Kyo, Lall, Chandana, Margolis, Daniel JA, McRae, Stephen E, Oto, Aytekin, Parsons, Rosaleen B, Patel, Nayana U, Pinto, Peter A, Polascik, Thomas J, Spilseth, Benjamin, Starcevich, Juliana B, Tammisetti, Varaha S, Taneja, Samir S, Turkbey, Baris, Verma, Sadhna, Ward, John F, Warlick, Christopher A, Weinberger, Andrew R, Yu, Jinxing, Zagoria, Ronald J, and Rosenkrantz, Andrew B

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Biomedical Imaging, Urologic Diseases, Prevention, Prostate Cancer, Aging, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Aged, Cross-Sectional Studies, Humans, Magnetic Resonance Imaging, Male, Predictive Value of Tests, Prostate, Prostatic Neoplasms, Radiology Information Systems, Reproducibility of Results, Retrospective Studies, Societies, Medical, Medical and Health Sciences, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

Background Prostate MRI is used widely in clinical care for guiding tissue sampling, active surveillance, and staging. The Prostate Imaging Reporting and Data System (PI-RADS) helps provide a standardized probabilistic approach for identifying clinically significant prostate cancer. Despite widespread use, the variability in performance of prostate MRI across practices remains unknown. Purpose To estimate the positive predictive value (PPV) of PI-RADS for the detection of high-grade prostate cancer across imaging centers. Materials and Methods This retrospective cross-sectional study was compliant with the HIPAA. Twenty-six centers with members in the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel submitted data from men with suspected or biopsy-proven untreated prostate cancer. MRI scans were obtained between January 2015 and April 2018. This was followed with targeted biopsy. Only men with at least one MRI lesion assigned a PI-RADS score of 2-5 were included. Outcome was prostate cancer with Gleason score (GS) greater than or equal to 3+4 (International Society of Urological Pathology grade group ≥2). A mixed-model logistic regression with institution and individuals as random effects was used to estimate overall PPVs. The variability of observed PPV of PI-RADS across imaging centers was described by using the median and interquartile range. Results The authors evaluated 3449 men (mean age, 65 years ± 8 [standard deviation]) with 5082 lesions. Biopsy results showed 1698 cancers with GS greater than or equal to 3+4 (International Society of Urological Pathology grade group ≥2) in 2082 men. Across all centers, the estimated PPV was 35% (95% confidence interval [CI]: 27%, 43%) for a PI-RADS score greater than or equal to 3 and 49% (95% CI: 40%, 58%) for a PI-RADS score greater than or equal to 4. The interquartile ranges of PPV at these same PI-RADS score thresholds were 27%-44% and 27%-48%, respectively. Conclusion The positive predictive value of the Prostate Imaging and Reporting Data System was low and varied widely across centers. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Milot in this issue.

Published
2020

5. Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer

Author

Privé, Bastiaan M., primary, Israël, Bas, additional, Janssen, Marcel J. R., additional, van der Leest, Marloes M. G., additional, de Rooij, Maarten, additional, van Ipenburg, Jolique A., additional, Jonker, Marianne, additional, Peters, Steffie M. B., additional, de Groot, Michel, additional, Zámecnik, Patrik, additional, Hoepping, Alexander, additional, Bomers, Joyce G., additional, Gotthardt, Martin, additional, Sedelaar, J. P. Michiel, additional, Barentsz, Jelle O., additional, van Oort, Inge M., additional, and Nagarajah, James, additional

Published
2024
Full Text
View/download PDF

7. A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging–directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men

Author

Wagensveld, Ivo M., Osses, Daniel F., Groenendijk, Pieter M., Zijta, Frank M., Busstra, Martijn B., Rociu, Elena, Barentsz, Jelle O., Michiel Sedelaar, J.P., Arbeel, Berber, Roeleveld, Ton, Geenen, Remy, Koeter, Ingrid, van der Meer, Saskia A., Cappendijk, Vincent, Somford, Rik, Klaver, Sjoerd, Van der Lely, Hans, Wolters, Tineke, Hellings, Willem, Leter, Maicle R., Van der Poel, Henk G., Heijmink, Stijn W.T.P.J., Debruyne, Frans, Immerzeel, Jos, Leijte, Joost, van Roermund, Joep, Miclea, Razvan, Planken, Erik, Vis, André N., Jan de Jong, Igle, Tijsterman, Jasper, Wolterbeek, Derk, Claessen, Anoesjka, Vrijhof, Eric, Nederend, Joost, Van Leenders, Geert J.L.H., Bangma, Chris H., Krestin, Gabriel P., Remmers, Sebastiaan, and Schoots, Ivo G.

Published
2022
Full Text
View/download PDF

8. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men

Author

Hendriks, Rianne J., van der Leest, Marloes M. G., Israël, Bas, Hannink, Gerjon, YantiSetiasti, Anglita, Cornel, Erik B., Hulsbergen-van de Kaa, Christina A., Klaver, O. Sjoerd, Sedelaar, J. P. Michiel, Van Criekinge, Wim, de Jong, Hans, Mulders, Peter F. A., Crawford, E. David, Veltman, Jeroen, Schalken, Jack A., Barentsz, Jelle O., and van Oort, Inge M.

Published
2021
Full Text
View/download PDF

9. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy

Author

Panebianco, Valeria, Villeirs, Geert, Weinreb, Jeffrey C., Turkbey, Baris I., Margolis, Daniel J., Richenberg, Jonathan, Schoots, Ivo G., Moore, Caroline M., Futterer, Jurgen, Macura, Katarzyna J., Oto, Aytekin, Bittencourt, Leonardo K., Haider, Masoom A., Salomon, Georg, Tempany, Clare M., Padhani, Anwar R., and Barentsz, Jelle O.

Published
2021
Full Text
View/download PDF

14. Is There an Added Value of Quantitative DCE-MRI by Magnetic Resonance Dispersion Imaging for Prostate Cancer Diagnosis?

Author

Jager, Auke, Oddens, Jorg R., Postema, Arnoud W., Miclea, Razvan L., Schoots, Ivo G., Nooijen, Peet G. T. A., van der Linden, Hans, Barentsz, Jelle O., Heijmink, Stijn W. T. P. J., Wijkstra, Hessel, Mischi, Massimo, and Turco, Simona

Subjects
BIOPSY, RESEARCH funding, DIAGNOSTIC imaging, DATA analysis, SURGERY, PATIENTS, RADICAL prostatectomy, RESEARCH evaluation, PROSTATE tumors, MAGNETIC resonance imaging, RETROSPECTIVE studies, CANCER patients, TERTIARY care, CHI-squared test, DESCRIPTIVE statistics, RESEARCH, STATISTICS, MEDICAL records, ACQUISITION of data, CONTRAST media, SENSITIVITY & specificity (Statistics), INTER-observer reliability
Abstract

Simple Summary: This multicenter, retrospective study assessed the added value of magnetic resonance dispersion imaging (MRDI), a quantitative analysis of dynamic contrast-enhanced MRI (DCE-MRI), alongside standard multiparametric MRI (mpMRI) for detecting clinically significant prostate cancer (csPCa). Seventy-six patients, including fifty-one with csPCa, who underwent mpMRI and radical prostatectomy, were included. Two radiologists evaluated mpMRI, MRDI and a combination of both, with histopathology serving as the reference standard. The study found that MRDI improved inter-observer agreement and enhanced csPCa detection when combined with mpMRI. MRDI enabled the detection of up to 20% more cases compared to mpMRI alone. With the role of DCE-MRI in the context of mpMRI being debated, this study suggests that quantitative analysis of DCE-MRI by MRDI could enhance csPCa detection and reduce variability between observers. In this multicenter, retrospective study, we evaluated the added value of magnetic resonance dispersion imaging (MRDI) to standard multiparametric MRI (mpMRI) for PCa detection. The study included 76 patients, including 51 with clinically significant prostate cancer (csPCa), who underwent radical prostatectomy and had an mpMRI including dynamic contrast-enhanced MRI. Two radiologists performed three separate randomized scorings based on mpMRI, MRDI and mpMRI+MRDI. Radical prostatectomy histopathology was used as the reference standard. Imaging and histopathology were both scored according to the Prostate Imaging-Reporting and Data System V2.0 sector map. Sensitivity and specificity for PCa detection were evaluated for mpMRI, MRDI and mpMRI+MRDI. Inter- and intra-observer variability for both radiologists was evaluated using Cohen's Kappa. On a per-patient level, sensitivity for csPCa for radiologist 1 (R1) for mpMRI, MRDI and mpMRI+MRDI was 0.94, 0.82 and 0.94, respectively. For the second radiologist (R2), these were 0.78, 0.94 and 0.96. R1 detected 4% additional csPCa cases using MRDI compared to mpMRI, and R2 detected 20% extra csPCa cases using MRDI. Inter-observer agreement was significant only for MRDI (Cohen's Kappa = 0.4250, p = 0.004). The results of this study show the potential of MRDI to improve inter-observer variability and the detection of csPCa. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial

Author

Privé, Bastiaan M., Janssen, Marcel J. R., van Oort, Inge M., Muselaers, Constantijn H. J., Jonker, Marianne A., van Gemert, Willemijn A., de Groot, Michel, Westdorp, Harm, Mehra, Niven, Verzijlbergen, J. Fred, Scheenen, Tom W. J., Zámecnik, Patrik, Barentsz, Jelle O., Gotthardt, Martin, Noordzij, Walter, Vogel, Wouter V., Bergman, Andries M., van der Poel, Henk G., Vis, André N., Oprea-Lager, Daniela E., Gerritsen, Winald R., Witjes, J. Alfred, and Nagarajah, James

Published
2021
Full Text
View/download PDF

23. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training

Author

de Rooij, Maarten, Israël, Bas, Tummers, Marcia, Ahmed, Hashim U., Barrett, Tristan, Giganti, Francesco, Hamm, Bernd, Løgager, Vibeke, Padhani, Anwar, Panebianco, Valeria, Puech, Philippe, Richenberg, Jonathan, Rouvière, Olivier, Salomon, Georg, Schoots, Ivo, Veltman, Jeroen, Villeirs, Geert, Walz, Jochen, and Barentsz, Jelle O.

Published
2020
Full Text
View/download PDF

25. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging–guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up

Author

Hamoen, Esther Hendrika Johanna, Hoeks, Caroline M.A., Somford, Diederik M., van Oort, Inge M., Vergunst, Henk, Oddens, Jorg R., Smits, Geert A., Bokhorst, Leonard P., Witjes, J. Alfred, Rovers, Maroeska M., Hulsbergen-van de Kaa, Christina A., and Barentsz, Jelle O.

Published
2019
Full Text
View/download PDF

28. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Author

Privé, Bastiaan M., Janssen, Marcel J. R., van Oort, Inge M., Muselaers, Constantijn H. J., Jonker, Marianne A., de Groot, Michel, Mehra, Niven, Verzijlbergen, J. Fred, Scheenen, Tom W. J., Zámecnik, Patrik, Barentsz, Jelle O., Gotthardt, Martin, Noordzij, Walter, Vogel, Wouter V., Bergman, Andries M., van der Poel, Henk G., Vis, André N., Oprea-Lager, Daniela E., Gerritsen, Winald R., Witjes, J. Alfred, and Nagarajah, James

Published
2020
Full Text
View/download PDF

29. Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia’s Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578–80

Author

Schilham, Melline G.M., primary, Rijpkema, Mark, additional, Scheenen, Tom, additional, Hermsen, Rick, additional, Barentsz, Jelle O., additional, Sedelaar, J.P.Michiel, additional, Kusters-Vandevelde, Heidi, additional, Kerkmeijer, Linda G.W., additional, Somford, Diederik M., additional, and Gotthardt, Martin, additional

Published
2023
Full Text
View/download PDF

30. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Author

Westdorp, Harm, Creemers, Jeroen H. A., van Oort, Inge M., Schreibelt, Gerty, Gorris, Mark A. J., Mehra, Niven, Simons, Michiel, de Goede, Anna L., van Rossum, Michelle M., Croockewit, Alexandra J., Figdor, Carl G., Witjes, J. Alfred, Aarntzen, Erik H. J. G., Mus, Roel D. M., Brüning, Mareke, Petry, Katja, Gotthardt, Martin, Barentsz, Jelle O., de Vries, I. Jolanda M., and Gerritsen, Winald R.

Published
2019
Full Text
View/download PDF

31. Supplementary Data from Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study

Author

Privé, Bastiaan M., primary, Peters, Steffie M.B., primary, Muselaers, Constantijn H.J., primary, van Oort, Inge M., primary, Janssen, Marcel J.R., primary, Sedelaar, J.P. Michiel, primary, Konijnenberg, Mark W., primary, Zámecnik, Patrik, primary, Uijen, Maike J.M., primary, Schilham, Melline G.M., primary, Eek, Annemarie, primary, Scheenen, Tom W.J., primary, Verzijlbergen, J. Fred, primary, Gerritsen, Winald R., primary, Mehra, Niven, primary, Kerkmeijer, Linda G.W., primary, Smeenk, Robert J., primary, Somford, Diederik M., primary, van Basten, Jean-Paul A., primary, Heskamp, Sandra, primary, Barentsz, Jelle O., primary, Gotthardt, Martin, primary, Witjes, J. Alfred, primary, and Nagarajah, James, primary

Published
2023
Full Text
View/download PDF

33. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come

Author

Schilham, Melline G.M., primary, Rijpkema, Mark, additional, Scheenen, Tom, additional, Hermsen, Rick, additional, Barentsz, Jelle O., additional, Michiel Sedelaar, J.P., additional, Kusters-Vandevelde, Heidi, additional, Kerkmeijer, Linda G.W., additional, Somford, Diederik M., additional, and Gotthardt, Martin, additional

Published
2022
Full Text
View/download PDF

35. Required Accuracy of MR-US Registration for Prostate Biopsies

Author

van de Ven, Wendy J. M., Litjens, Geert J. S., Barentsz, Jelle O., Hambrock, Thomas, Huisman, Henkjan J., Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Sudan, Madhu, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Vardi, Moshe Y., Series editor, Weikum, Gerhard, Series editor, Madabhushi, Anant, editor, Dowling, Jason, editor, Huisman, Henkjan, editor, and Barratt, Dean, editor

Published
2011
Full Text
View/download PDF

40. Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score

Author

Pecoraro, Martina, primary, Turkbey, Baris, additional, Purysko, Andrei S., additional, Girometti, Rossano, additional, Giannarini, Gianluca, additional, Villeirs, Geert, additional, Roberto, Michela, additional, Catalano, Carlo, additional, Padhani, Anwar R., additional, Barentsz, Jelle O., additional, and Panebianco, Valeria, additional

Published
2022
Full Text
View/download PDF

46. An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer

Author

Privé, Bastiaan M., primary, Muselaers, Constantijn H. J., additional, van Oort, Inge M., additional, Janssen, Marcel J. R., additional, Peters, Steffie M. B., additional, van Gemert, Willemijn A. M., additional, Uijen, Maike J. M., additional, Schilham, Melline M. G., additional, Sedelaar, J. P. Michiel, additional, Westdorp, Harm, additional, Mehra, Niven, additional, Gotthardt, Martin, additional, Barentsz, Jelle O., additional, Gerritsen, Winald R., additional, Witjes, J. Alfred, additional, and Nagarajah, James, additional

Published
2022
Full Text
View/download PDF

48. Radiomic combination of spatial and temporal features extracted from DCE-MRI for prostate cancer detection ∗

Author

Fernandes, Catarina Dinis, Mischi, Massimo, Wijkstra, Hessel, Barentsz, Jelle O., Heijmink, Stijn W. T. P. J., Turco, Simona, Biomedical Diagnostics Lab, Eindhoven MedTech Innovation Center, Signal Processing Systems, Center for Care & Cure Technology Eindhoven, EAISI Health, Urology, APH - Quality of Care, CCA - Cancer Treatment and Quality of Life, CCA - Imaging and biomarkers, and APH - Personalized Medicine

Subjects
Machine Learning, Male, SDG 3 - Good Health and Well-being, Humans, Prostatic Neoplasms, Multiparametric Magnetic Resonance Imaging, SDG 3 – Goede gezondheid en welzijn, skin and connective tissue diseases, Magnetic Resonance Imaging, Retrospective Studies
Abstract

Multi-parametric MRI is part of the standard prostate cancer (PCa) diagnostic protocol. Recent imaging guidelines (PI-RADS v2) downgraded the value of Dynamic Contrast-Enhanced (DCE)-MRI in the diagnosis of PCa. A purely qualitative analysis of the DCE-MRI time series, as it is generally done by radiologists, might indeed overlook information on the microvascular architecture and function. In this study, we investigate the discriminative power of quantitative imaging features derived from texture and pharmacokinetic analysis of DCE-MRI. In 605 regions of interest (benign and malignant tissue) delineated in 80 patients, we found through independent cross-validation that a subset of quantitative spatial and temporal features extracted from DCE-MRI and incorporated in machine learning classifiers obtains a good diagnostic performance (AUC = 0.80-0.86) in distinguishing malignant from benign regions.Clinical Relevance- These findings highlight the underlying potential of quantitative DCE-derived radiomic features in identifying PCa by MRI.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results